Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Matthew J. Maurer, Emmanuel Bachy, Hervé Ghesquières, Stephen Maxted Ansell, Grzegorz S Nowakowski, Carrie A Thompson, David J. Inwards, Cristine Allmer, Catherine Chassagne-Clément, Emmanuelle Nicolas-Virelizier, Catherine Sebban, Laure Lebras, Clementine Sarkozy, William R. Macon, Andrew L Feldman, Sergei I. Syrbu, Alexandra Traverse-Glehan, Bertrand Coiffier, Susan L Slager, George J. WeinerThomas Elmer Witzig, Thomas Matthew Habermann, Gilles Salles, James R Cerhan, Brian K. Link

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event-free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1-3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002-2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re-treatment, or death due to any cause. OS was compared to age-and-sex-matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR=3.72, 95%CI: 2.78-4.88; Lyon SMR=8.74, 95%CI: 5.41-13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR=0.73, 95%CI: 0.56-0.94, Lyon SMR=1.02, 95%CI: 0.58-1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR=17.63, 95%CI:11.97-25.02, Lyon SMR=19.10, 95%CI:9.86-33.36; EFS24 failure: MER SMR=13.02, 95%CI:9.31-17.74, Lyon SMR=7.22, 95%CI:4.13-11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL.

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StateAccepted/In press - 2016

Fingerprint

Follicular Lymphoma
Confidence Intervals
Molecular Epidemiology
Mortality
Survival
Disease-Free Survival
Population
France
Registries
Lymphoma
Outcome Assessment (Health Care)
Recurrence

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology

Cite this

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. / Maurer, Matthew J.; Bachy, Emmanuel; Ghesquières, Hervé; Ansell, Stephen Maxted; Nowakowski, Grzegorz S; Thompson, Carrie A; Inwards, David J.; Allmer, Cristine; Chassagne-Clément, Catherine; Nicolas-Virelizier, Emmanuelle; Sebban, Catherine; Lebras, Laure; Sarkozy, Clementine; Macon, William R.; Feldman, Andrew L; Syrbu, Sergei I.; Traverse-Glehan, Alexandra; Coiffier, Bertrand; Slager, Susan L; Weiner, George J.; Witzig, Thomas Elmer; Habermann, Thomas Matthew; Salles, Gilles; Cerhan, James R; Link, Brian K.

In: American Journal of Hematology, 2016.

Research output: Contribution to journalArticle

Maurer, MJ, Bachy, E, Ghesquières, H, Ansell, SM, Nowakowski, GS, Thompson, CA, Inwards, DJ, Allmer, C, Chassagne-Clément, C, Nicolas-Virelizier, E, Sebban, C, Lebras, L, Sarkozy, C, Macon, WR, Feldman, AL, Syrbu, SI, Traverse-Glehan, A, Coiffier, B, Slager, SL, Weiner, GJ, Witzig, TE, Habermann, TM, Salles, G, Cerhan, JR & Link, BK 2016, 'Early event status informs subsequent outcome in newly diagnosed follicular lymphoma', American Journal of Hematology. https://doi.org/10.1002/ajh.24492
Maurer, Matthew J. ; Bachy, Emmanuel ; Ghesquières, Hervé ; Ansell, Stephen Maxted ; Nowakowski, Grzegorz S ; Thompson, Carrie A ; Inwards, David J. ; Allmer, Cristine ; Chassagne-Clément, Catherine ; Nicolas-Virelizier, Emmanuelle ; Sebban, Catherine ; Lebras, Laure ; Sarkozy, Clementine ; Macon, William R. ; Feldman, Andrew L ; Syrbu, Sergei I. ; Traverse-Glehan, Alexandra ; Coiffier, Bertrand ; Slager, Susan L ; Weiner, George J. ; Witzig, Thomas Elmer ; Habermann, Thomas Matthew ; Salles, Gilles ; Cerhan, James R ; Link, Brian K. / Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. In: American Journal of Hematology. 2016.
@article{4fb2e2d3625444c6bc8ca3b743c2ddba,
title = "Early event status informs subsequent outcome in newly diagnosed follicular lymphoma",
abstract = "Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event-free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1-3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002-2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re-treatment, or death due to any cause. OS was compared to age-and-sex-matched survival in the general US population using standardized mortality ratios (SMR) and 95{\%} confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR=3.72, 95{\%}CI: 2.78-4.88; Lyon SMR=8.74, 95{\%}CI: 5.41-13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR=0.73, 95{\%}CI: 0.56-0.94, Lyon SMR=1.02, 95{\%}CI: 0.58-1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR=17.63, 95{\%}CI:11.97-25.02, Lyon SMR=19.10, 95{\%}CI:9.86-33.36; EFS24 failure: MER SMR=13.02, 95{\%}CI:9.31-17.74, Lyon SMR=7.22, 95{\%}CI:4.13-11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL.",
author = "Maurer, {Matthew J.} and Emmanuel Bachy and Herv{\'e} Ghesqui{\`e}res and Ansell, {Stephen Maxted} and Nowakowski, {Grzegorz S} and Thompson, {Carrie A} and Inwards, {David J.} and Cristine Allmer and Catherine Chassagne-Cl{\'e}ment and Emmanuelle Nicolas-Virelizier and Catherine Sebban and Laure Lebras and Clementine Sarkozy and Macon, {William R.} and Feldman, {Andrew L} and Syrbu, {Sergei I.} and Alexandra Traverse-Glehan and Bertrand Coiffier and Slager, {Susan L} and Weiner, {George J.} and Witzig, {Thomas Elmer} and Habermann, {Thomas Matthew} and Gilles Salles and Cerhan, {James R} and Link, {Brian K.}",
year = "2016",
doi = "10.1002/ajh.24492",
language = "English (US)",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

AU - Maurer, Matthew J.

AU - Bachy, Emmanuel

AU - Ghesquières, Hervé

AU - Ansell, Stephen Maxted

AU - Nowakowski, Grzegorz S

AU - Thompson, Carrie A

AU - Inwards, David J.

AU - Allmer, Cristine

AU - Chassagne-Clément, Catherine

AU - Nicolas-Virelizier, Emmanuelle

AU - Sebban, Catherine

AU - Lebras, Laure

AU - Sarkozy, Clementine

AU - Macon, William R.

AU - Feldman, Andrew L

AU - Syrbu, Sergei I.

AU - Traverse-Glehan, Alexandra

AU - Coiffier, Bertrand

AU - Slager, Susan L

AU - Weiner, George J.

AU - Witzig, Thomas Elmer

AU - Habermann, Thomas Matthew

AU - Salles, Gilles

AU - Cerhan, James R

AU - Link, Brian K.

PY - 2016

Y1 - 2016

N2 - Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event-free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1-3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002-2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re-treatment, or death due to any cause. OS was compared to age-and-sex-matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR=3.72, 95%CI: 2.78-4.88; Lyon SMR=8.74, 95%CI: 5.41-13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR=0.73, 95%CI: 0.56-0.94, Lyon SMR=1.02, 95%CI: 0.58-1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR=17.63, 95%CI:11.97-25.02, Lyon SMR=19.10, 95%CI:9.86-33.36; EFS24 failure: MER SMR=13.02, 95%CI:9.31-17.74, Lyon SMR=7.22, 95%CI:4.13-11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL.

AB - Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event-free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1-3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002-2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re-treatment, or death due to any cause. OS was compared to age-and-sex-matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR=3.72, 95%CI: 2.78-4.88; Lyon SMR=8.74, 95%CI: 5.41-13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR=0.73, 95%CI: 0.56-0.94, Lyon SMR=1.02, 95%CI: 0.58-1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR=17.63, 95%CI:11.97-25.02, Lyon SMR=19.10, 95%CI:9.86-33.36; EFS24 failure: MER SMR=13.02, 95%CI:9.31-17.74, Lyon SMR=7.22, 95%CI:4.13-11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL.

UR - http://www.scopus.com/inward/record.url?scp=84984829657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984829657&partnerID=8YFLogxK

U2 - 10.1002/ajh.24492

DO - 10.1002/ajh.24492

M3 - Article

C2 - 27465588

AN - SCOPUS:84984829657

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -